Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel highaffinity antiIgE antibody, in atopic subjects

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects J. P. Arm, I. Bottoli, A. Skerjanec, D. Floch, A. Groenewegen, S. Maahs, C. E. Owen, I. Jones and P. J. Lowe Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA, USA, Primary Care, Novartis Pharma AG, Basel, Switzerland, Preclinical Safety, Novartis Institute for Biomedical Research, Basel, Switzerland, Biomarker Development, Novartis Pharma AG, Basel, Switzerland, Clinical Sciences and Innovation, Novartis Institute for Biomedical Research, East Hanover, NJ, USA, Novartis Institute for Biomedical Research, Horsham, West Sussex, UK, NIBR Biometrics and Statistical Science, Novartis Pharma AG, Basel, Switzerland and Advanced Quantitative Sciences, Novartis Pharma AG, Basel, Switzerland